RecruitingNCT05126160
Immune Score Based Radiomics in Nasopharyngeal Carcinoma
Immune Score Based Radiomics in Nasopharyngeal Carcinoma (IMRAN Study)
Sponsor
Zhejiang Cancer Hospital
Enrollment
494 participants
Start Date
Nov 5, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
In nasopharyngeal carcinoma (NPC), tumor, node and metastasis (TNM) staging system is the main tool for determining treatment strategy and assessment of prognosis. However, the prognoses of patients with the same TNM stage after similar treatment vary widely. The aim of this study is to establish an immune score based radiomic staging system for NPC.
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria2
- Patients with newly histologically confirmed non-keratinizing/keratinizing carcinoma.
- ECOG Performance status: 0-1 With normal liver function test (ALT, AST ≤2.5ULN) Renal: creatinine clearance ≥60ml/min Without hematopathy,marrow: WBC \>4\*109/L, HGB\>90G/L, and PLT\>100\*109/L. Written informed consent
Exclusion Criteria1
- Contraindications for MRI scan Prior malignancy (except adequately treated carcinoma in-situ of the cervix or · basal/squamous cell carcinoma of the skin) Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume) Patient is pregnant or lactating Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \>1.5×ULN), or emotional disturbance.
Interventions
DIAGNOSTIC_TESTImmune Score Based Radiomics
To establish an immune score based radiomic staging system for nasopharyngeal carcinoma
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05126160
Related Trials
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
NCT059417413 locations
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
NCT0623972726 locations
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
NCT060592611 location
Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
NCT065925991 location
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
NCT064753001 location